title: [Contraception by cyclic treatment with buserelin and progesterone].
abstract: Hormonal contraception with a combination of a GnRH-agonist (Buserelin) and progesterone was achieved in 47 high risk patients in 547 cycles. In these patients, oral contraceptives were contraindicated because of severe cardiovascular diseases, thromboembolic complications, benign liver tumours, advanced diabetes, terminal kidney insufficiency and severe migraine. Buserelin was administered intranasally in one daily dose of 300-400 micrograms from the 1st day to the 21st day, one dose of 100 mg of Progesterone was given intravaginally daily from the 12th day to the 21st day. Under these conditions, average E2 concentrations were found in the range of 50-60 pg/ml. The discontinuation of progesterone replacement resulted in withdrawal bleeding. Cycle control was acceptable. In 4 cases, this contraceptive regimen had to be discontinued because of side effects or paradox reactions. One patient conceived. In conclusion, GnRH-analogues in a moderate dose can be used to inhibit ovulation without inhibiting follicular maturation and adequate oestrogen production. This costly regimen of contraception requires strict indication and careful monitoring.
authors.affiliation: Abteilung für Klinische Endokrinologie, Universitäts-Frauenklinik, Freiburg.
authors.forename: P
authors.initials: P
authors.lastname: Wieacker
authors.forename: M
authors.initials: M
authors.lastname: Breckwoldt
authors.forename: M
authors.initials: M
authors.lastname: Greif
authors.forename: F
authors.initials: F
authors.lastname: Geisthövel
mesh_terms: D000281:Administration, Intranasal; D000282:Administration, Intravaginal; D000328:Adult; D002064:Buserelin / Q000008:administration & dosage* / Q000009:adverse effects; D003271:Contraceptive Agents, Female; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010060:Ovulation / Q000187:drug effects; D011247:Pregnancy; D011374:Progesterone / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D003271:Contraceptive Agents, Female; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin
vernacular_title: Antikonzeption durch zyklische Behandlung mit Buserelin und Progesteron.